Q-omics provides the consensus-scored PRPF38A profile across patient tissues and cancer cell-line models. PRPF38A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRPF38A is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, PRPF38A protein abundance shows 28,304 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KICH, and LSCC as cancer lineages where PRPF38A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRPF38A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRPF38A survival associations across molecular data types. PRPF38A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRPF38A RNA expression–survival associations across cancer types. High PRPF38A expression shows unfavorable associations in ACC, KIRP, LIHC, MESO and SARC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRPF38A RNA expression.
This table summarizes PRPF38A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRPF38A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRPF38A shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, STAD, HNSC and CHOL. The KICH box plot shows higher PRPF38A RNA expression in normal versus tumor tissue (log2 FC = −2.084, t-test p < 0.001).
This table shows molecular features associated with PRPF38A in patient tissues and cancer cell lines. In patient samples, PRPF38A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRPF38A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
